Your browser doesn't support javascript.
loading
Chilblain lupus-like cutaneous reaction associated with systemic lupus erythematosus induced by immune checkpoint inhibitor.
Takeda, Koichi; Nakano, Kenji; Udagawa, Shohei; Fukuda, Naoki; Nishizawa, Aya; Ono, Makiko; Urasaki, Tetsuya; Tomomatsu, Junichi; Mochizuki, Toshiaki; Shiga, Taro; Kogawa, Takahiro; Takahashi, Shunji; Kitano, Shigehisa.
Afiliación
  • Takeda K; Department of Onco-Rheumatology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Nakano K; Department of Infectious Diseases, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Udagawa S; Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Fukuda N; Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Nishizawa A; Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Ono M; Department of Dermatology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Urasaki T; Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Tomomatsu J; Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Mochizuki T; Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Shiga T; Department of Emergency Medicine, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Kogawa T; Department of Onco-Cardiology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Takahashi S; Division of Early Clinical Development for Cancer, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Kitano S; Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Rheumatology (Oxford) ; 61(1): e13-e14, 2021 12 24.
Article en En | MEDLINE | ID: mdl-34463707
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Lupus Eritematoso Cutáneo / Eritema Pernio / Anticuerpos Monoclonales Humanizados / Inhibidores de Puntos de Control Inmunológico Tipo de estudio: Risk_factors_studies Límite: Female / Humans / Middle aged Idioma: En Revista: Rheumatology (Oxford) Asunto de la revista: REUMATOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Lupus Eritematoso Cutáneo / Eritema Pernio / Anticuerpos Monoclonales Humanizados / Inhibidores de Puntos de Control Inmunológico Tipo de estudio: Risk_factors_studies Límite: Female / Humans / Middle aged Idioma: En Revista: Rheumatology (Oxford) Asunto de la revista: REUMATOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido